Search Results for “AstraZeneca” – Page 26 – media

Mercks to Lead Squamous Lung Cancer Treatment With Keytruda

Pharma giant Merck & Co. revealed Keytruda had perfectly completed its final-stage research on the drug for previously untreated patients with skin cancer, who represent about 25% to 30% of the overall market.
- Source: Ddu
- 640
- May 24, 2018
cancer Company Insight Merck
Rise in China’s Global Pharma Market up to $175 billion by 2022 – Market Prediction

Though the US stands first in the race in terms of sales and growth, it is highly believed that China would reach the peak in the pharma market by 2022. At present, since there has been a decrease in public health funding, there has been a slight fall in pharmerging countries like Brazil, Russia, India and China (BRIC). But it is believed that the condition of these pharmerging countries will improve in the next five years [1].
- Source: Ddu
- 822
- May 24, 2018
China Market Views pharmaceutical drugs
Biotechnology Company Abpro postpones $69M IPO

According to reports, the biotechnology company Abpro has rescheduled its $96 million IPO, delaying a capital infusion it hoped would support the first clinical trials of its lead product candidates over the next year.
- Source: Ddu
- 606
- May 14, 2018
biotech Company Insights IPO
Lynparza tablets (ovarian cancer) given go-ahead by European regulators

With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
- Source: drugdu
- 750
- May 10, 2018
AstraZeneca cancer New Approvals pharma
NEJM editorial slams design of GSK’s pivotal trial of 3-in-1 COPD drug Trelegy

GSK is shifting resources towards key therapeutic classes, including respiratory disease.
- Source: fiercepharma.
- 600
- April 24, 2018
Company Insight GSK respiratory disease Trelegy Ellipta
Hanmi Pharma gives up on development of lung cancer drug Olita

South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
- Source: koreaher
- 2,360
- April 20, 2018
Clinical Trials Company Insights Olita
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 876
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Sanofi’s PD-1 inhibitor starts EU review for skin cancer

The EMA has kicked off its review of Sanofi and Regeneron’s immuno-oncology drug cemiplimab, which is aiming to become the sixth drug in the PD-1/PD-L1 inhibitor class to reach the market.
- Source: Pmlive
- 552
- April 8, 2018
cemiplimab immuno-oncology New Approvals
Lokelma approved in the EU for the treatment of adults with hyperkalaemia

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.
- Source: Worldpharmanews
- 578
- March 27, 2018
hyperkalaemia Lokelma New Approvals
GSK pharma boss Miels rejigs commercial operations to stoke new launches Trelegy, Shingrix

GlaxoSmithKline's new CEO Emma Walmsley isn’t the only one shaking things up at the top of the British drugmaker.
- Source: fiercepharma.
- 706
- March 23, 2018
Company Insights GlaxoSmithKline Shingrixin vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.